单位：[1]Department of Respiratory and Critical Care Medicine, Key Laboratory of Pulmonary Diseases of Health Ministry, Key Site of National Clinical Research Center for Respiratory Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China.内科学系呼吸内科华中科技大学同济医学院附属同济医院[2]Department of Respiratory and Critical Care Medicine, Key Laboratory of Pulmonary Diseases of Health Ministry, Key Site of National Clinical Research Center for Respiratory Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China. Electronic address: sxu@hust.edu.cn.内科学系呼吸内科华中科技大学同济医学院附属同济医院
第一作者单位：[1]Department of Respiratory and Critical Care Medicine, Key Laboratory of Pulmonary Diseases of Health Ministry, Key Site of National Clinical Research Center for Respiratory Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China.
推荐引用方式(GB/T 7714)：
Bao Chen,Liu Chao,Liu Qian,et al.Corrigendum to "Liproxstatin-1 alleviates LPS/IL-13-induced bronchial epithelial cell injury and neutrophilic asthma in mice by inhibiting ferroptosis" [Int. Immunopharmacol. 109 (2022) 108770[J].INTERNATIONAL IMMUNOPHARMACOLOGY.2023,115:doi:10.1016/j.intimp.2022.109482.
APA：
Bao Chen,Liu Chao,Liu Qian,Hua Lijuan,Hu Jiannan...&Xu Shuyun.(2023).Corrigendum to "Liproxstatin-1 alleviates LPS/IL-13-induced bronchial epithelial cell injury and neutrophilic asthma in mice by inhibiting ferroptosis" [Int. Immunopharmacol. 109 (2022) 108770.INTERNATIONAL IMMUNOPHARMACOLOGY,115,
MLA：
Bao Chen,et al."Corrigendum to "Liproxstatin-1 alleviates LPS/IL-13-induced bronchial epithelial cell injury and neutrophilic asthma in mice by inhibiting ferroptosis" [Int. Immunopharmacol. 109 (2022) 108770".INTERNATIONAL IMMUNOPHARMACOLOGY 115.(2023)
